A man collapsed inside the Oval Office during an event where President Donald Trump announced a new initiative aimed at providing subsidized access to weight-loss prescription drugs.

The individual, initially identified on social media as Gordon Findlay of Novo Nordisk, was later the subject of conflicting reports regarding his identity.

Health Scare Interrupts Oval Office Announcement

Live television footage showed him suddenly losing balance and being assisted to the floor by those nearby. Medicare and Medicaid Administrator Mehmet Oz was seen supporting the man as he was lowered safely.

President Trump stood from behind the Resolute Desk but did not intervene. Health Secretary Robert F. Kennedy Jr. appeared to move quickly out of frame, while members of the press were asked to leave the room.

White House Press Secretary Karoline Leavitt later stated that “a representative with one of the companies fainted” and confirmed that the man was in stable condition. The White House Medical Unit responded immediately, and the press event was briefly paused before resuming.

Focus on Drug Pricing and Accessibility

The event centered on a new agreement between Eli Lilly and Novo Nordisk to reduce prices of GLP-1 receptor agonists — drugs used for weight loss and diabetes management, such as Wegovy and Zepbound. These medications have shown strong results in clinical trials but remain costly for many patients.

The initiative seeks to make these treatments more affordable through federal subsidies, as obesity rates in the United States show early signs of decline